BONSITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BONSITY (BONSITY).
Selective estrogen receptor modulator (SERM); binds to estrogen receptors, exerting agonistic effects on bone and lipid metabolism and antagonistic effects on breast and uterine tissue.
| Metabolism | Extensively metabolized in the liver primarily by glucuronidation (UGT1A1, UGT1A8, UGT1A9) and minor oxidation by CYP3A4. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination comprises 20-25% as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 24-30 hours; this supports once-daily dosing. Half-life may be prolonged in renal impairment. |
| Protein binding | Approximately 85-90% bound primarily to albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral: 70-80%; subcutaneous: 90-100%. |
| Onset of Action | Oral: 1-2 hours; subcutaneous: 30-60 minutes; intravenous: within 15 minutes. |
| Duration of Action | Duration of action is approximately 24 hours, consistent with once-daily dosing. Clinical effect persists for the entire dosing interval. |
10 mg orally once daily, taken with or without food.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min. For GFR 15-29 mL/min, reduce dose to 5 mg once daily. Not recommended for GFR <15 mL/min or dialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 5 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric patients; no dosing recommendations available. |
| Geriatric use | Initiate at 5 mg once daily for patients ≥75 years of age; titrate based on tolerability. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BONSITY (BONSITY).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio unknown; excreted in human milk and may cause serious adverse effects in nursing infants. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: high risk of neural tube defects, cardiac malformations, and craniofacial anomalies. Second and third trimesters: risk of intrauterine growth restriction, oligohydramnios, and fetal renal impairment. |
| Fetal Monitoring |
■ FDA Black Box Warning
Increased risk of venous thromboembolic events (deep vein thrombosis, pulmonary embolism) and death from stroke. Risk must be weighed against benefits.
| Serious Effects |
Active or past history of venous thromboembolic events (DVT, PE); women who are or may become pregnant; hepatic impairment (Child-Pugh class B or C); hypersensitivity to raloxifene or any component.
| Precautions | Venous thromboembolism (VTE) risk; stroke risk; atrial fibrillation; cholelithiasis; hypertriglyceridemia; uterine malignancy; cataract formation; liver enzyme elevations. |
| Food/Dietary | No clinically significant food interactions. BONSITY can be taken with or without food. Avoid grapefruit products only if specifically advised by the prescriber, as no grapefruit interaction has been established for setmelanotide. |
Loading safety data…
| Monitor maternal renal function, liver enzymes, and blood pressure. Assess fetal growth via ultrasound every 4 weeks. Perform fetal echocardiography at 20-22 weeks gestation. |
| Fertility Effects | May impair female fertility through ovarian toxicity and menstrual irregularities. Reversible upon discontinuation. Male fertility may be reduced due to spermatogenesis impairment. |
| Clinical Pearls | BONSITY (setmelanotide) is an MC4R agonist indicated for chronic weight management in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. Titrate dose over 2 weeks to minimize adverse events. Monitor for hypersensitivity reactions, including serum sickness. Do not use in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) or end-stage renal disease. Avoid co-administration with drugs that affect the melanocortin pathway, such as opioid antagonists (e.g., naltrexone) which may reduce efficacy. Assess for depression and suicidal ideation prior to and during treatment. |
| Patient Advice | BONSITY is a daily injection that helps regulate appetite and weight loss by targeting a specific genetic defect. · You will need to confirm your genetic test results (POMC, PCSK1, or LEPR deficiency) before starting treatment. · Inject BONSITY subcutaneously in the abdomen, thigh, or upper arm, rotating sites daily. · Administer BONSITY once daily, with or without food. · Do not take BONSITY if you are pregnant, breastfeeding, or planning to become pregnant. · Common side effects include injection site reactions, nausea, vomiting, and diarrhea. Report any severe or persistent symptoms to your doctor. · Seek immediate medical help if you experience symptoms of a serious allergic reaction: hives, difficulty breathing, swelling of face or throat. · Your doctor will monitor your mental health; report any changes in mood, depression, or suicidal thoughts. · Avoid taking medications that may interfere with BONSITY, such as opioid pain relievers or naltrexone. · Store BONSITY in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. |